Free Trial
NASDAQ:JSPRW

Jasper Therapeutics (JSPRW) Stock Price, News & Analysis

$0.10 -0.01 (-10.23%)
As of 05/23/2025 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Jasper Therapeutics Stock (NASDAQ:JSPRW)

Key Stats

Today's Range
$0.10
$0.10
50-Day Range
$0.08
$0.15
52-Week Range
$0.06
$0.25
Volume
110 shs
Average Volume
6,151 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Receive JSPRW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JSPRW Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Jasper Therapeutics (JSPR) Gets a Buy from UBS
Jasper Therapeutics (JSPR) Receives a Buy from Credit Suisse
See More Headlines

JSPRW Stock Analysis - Frequently Asked Questions

Jasper Therapeutics' stock was trading at $0.2096 at the start of the year. Since then, JSPRW stock has decreased by 52.3% and is now trading at $0.10.
View the best growth stocks for 2025 here
.

Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:JSPRW
Web
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:JSPRW) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners